Cell-free DNA concentration and integrity as a screening tool for cancer
Cell-free DNA concentration and integrity as a screening tool for cancer
复制标题
DOI：
10.4103/0019-509x.118721
复制
发表时间：
2013-07-01
影响因子：
1
通讯作者：
Abo-El-Eneen, Marwa S.
中科院分区：
文献类型：
--
作者：
Zaher, Ebtsam R.;Anwar, Medhat M.;Abo-El-Eneen, Marwa S.
研究目的：本研究的目的是评估恶性和非恶性疾病患者和对照组中游离DNA（CFDNA）的浓度和完整性，以研究其作为癌症筛查试验的价值，并将其与癌症患者的临床病理参数相关联。材料与方法：研究分为三组：第一组：120名癌症患者，第二组：120名良性疾病患者和第三组：120名正常健康志愿者作为对照。从每例受试者中采集一份血浆样本。从血浆中纯化CFDNA，然后测量其浓度，并通过PCR扩增100、200、400和800 bp条带评估完整性。结果：肺癌组CFDNA水平与良性病变组及对照组比较，差异有高度显著性。癌症组与正常组和良性组的ROC曲线的AUC分别为0.962和0.895，表明CFDNA作为癌症标志物的有效性。至于完整性，正常和良性受试者仅在100和200 bp处显示两条带，而所有癌症患者均显示400 bp带，其中78%的患者具有800 bp带，其存在与血管浸润相关。结论：CFDNA浓度和完整性的联合使用是癌症的通用筛查试验的候选者。在为测试设定合适的界限后，它可能被应用于识别癌症患者，特别是在有易感因素的受试者中。由于成本较低，CFDNA浓度可以应用于大规模筛查，并且对于具有与正常和良性受试者的值重叠的值的患者，建议使用更昂贵但更具体的完整性测试。
Aim of the Study: This study aims to evaluate cell-free DNA (CFDNA) concentration and integrity in patients with malignant and nonmalignant diseases and in controls to investigate their value as a screening test for cancer, and to correlate them with clinicopathological parameters of cancer patients. Materials and Methods: The study included three groups; group I: 120 cancer patients, group II: 120 patients with benign diseases and group III: 120 normal healthy volunteers as control. One plasma sample was collected from each subject. CFDNA was purified from the plasma then its concentration was measured and integrity was assessed by PCR amplification of 100, 200, 400, and 800 bp bands. Results: There was a highly significant difference in CFDNA levels between cancer group and each of benign and control groups. AUC of ROC curve for cancer group versus normal and benign groups were 0.962 and 0.895, which indicated the efficiency of CFDNA as a marker of cancer. As for integrity, normal and benign subjects showed only two bands at 100 and 200 bp, while all cancer patients demonstrated the 400 bp band and 78% of them had the 800 bp whose presence correlated with vascular invasion. Conclusion: The combined use of CFDNA concentration and integrity is a candidate for a universal screening test of cancer. Upon setting suitable boundaries for the test it might be applied to identify cancer patients, particularly among subjects with predisposing factors. Being less expensive, CFDNA concentration could be applied for mass screening and for patients with values overlapping those of normal and benign subjects, the use of the more expensive, yet more specific, integrity test is suggested.